Stockreport

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease

Axon Enterprise, Inc.  (AXON) 
Last axon enterprise, inc. earnings: 2/7 04:15 pm Check Earnings Report
US:NYSE Investor Relations: investors.axovant.com/investors/sec-filings
PDF Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company deve [Read more]